Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peptide Receptor Radionuclide Therapy Using 90Y- and 177Lu-DOTATATE Modulating Atherosclerotic Plaque Inflammation: Longitudinal Monitoring by 68Ga-DOTATATE Positron Emissions Tomography/Computer Tomography.
Rubinstein G, Ilhan H, Bartenstein P, Lehner S, Hacker M, Todica A, Zacherl MJ, Fischer M. Rubinstein G, et al. Among authors: ilhan h. Diagnostics (Basel). 2024 Nov 7;14(22):2486. doi: 10.3390/diagnostics14222486. Diagnostics (Basel). 2024. PMID: 39594152 Free PMC article.
Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after 177Lu-PSMA-617 Radioligand Therapy.
Völter F, Mittlmeier L, Gosewisch A, Brosch-Lenz J, Gildehaus FJ, Zacherl MJ, Beyer L, Stief CG, Holzgreve A, Rübenthaler J, Cyran CC, Böning G, Bartenstein P, Todica A, Ilhan H. Völter F, et al. Among authors: ilhan h. Diagnostics (Basel). 2021 Mar 3;11(3):428. doi: 10.3390/diagnostics11030428. Diagnostics (Basel). 2021. PMID: 33802417 Free PMC article.
Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors.
Zellmer J, Yen HY, Kaiser L, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR, Ilhan H. Zellmer J, et al. Among authors: ilhan h. Biomedicines. 2022 Dec 1;10(12):3102. doi: 10.3390/biomedicines10123102. Biomedicines. 2022. PMID: 36551858 Free PMC article.
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.
Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S, Bartenstein P, Bengel F, Schatka I, Muegge DO, Papp L, Zsótér N, Große-Ophoff T, Essler M, Bundschuh RA. Werner RA, et al. Among authors: ilhan h. Oncotarget. 2017 Jan 24;8(4):7039-7049. doi: 10.18632/oncotarget.12402. Oncotarget. 2017. PMID: 27705948 Free PMC article. Clinical Trial.
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
Werner RA, Ilhan H, Lehner S, Papp L, Zsótér N, Schatka I, Muegge DO, Javadi MS, Higuchi T, Buck AK, Bartenstein P, Bengel F, Essler M, Lapa C, Bundschuh RA. Werner RA, et al. Among authors: ilhan h. Mol Imaging Biol. 2019 Jun;21(3):582-590. doi: 10.1007/s11307-018-1252-5. Mol Imaging Biol. 2019. PMID: 30014345
212 results